Content about ViiV Healthcare

December 18, 2013

Lupin has launched a generic drug for treating HIV, following its victory in a patent-infringement suit in federal court, the Indian drug maker said Wednesday.

BALTIMORE — Lupin has launched a generic drug for treating HIV, following its victory in a patent-infringement suit in federal court, the Indian drug maker said Wednesday.

Lupin's U.S. subsidiary launched its generic version of ViiV Healthcare's Trizivir (abacavir sulfate; lamivudine; zidovudine) tablets in the 300-mg/150-mg/300-mg strength. The launch follows a ruling by the U.S. District Court for the District of Delaware that the drug did not infringe on Viiv's patent.

September 4, 2013

A joint venture founded by GlaxoSmithKline and Pfizer focused on treatments for HIV has expanded its support of community organizations in the South.

RESEARCH TRIANGLE PARK, N.C. — A joint venture founded by GlaxoSmithKline and Pfizer focused on treatments for HIV has expanded its support of community organizations in the South.

February 19, 2013

The Food and Drug Administration has granted priority review to an experimental drug made by ViiV Healthcare for HIV, the company, a joint venture between British drug maker GlaxoSmithKline and American drug maker Pfizer, announced.

LONDON — The Food and Drug Administration has granted priority review to an experimental drug made by ViiV Healthcare for HIV, the company, a joint venture between British drug maker GlaxoSmithKline and American drug maker Pfizer, announced.

The FDA gave the designation to dolutegravir, designed for use in combination with other antiretrovirual drugs in adults and adolescents. The agency gives priority review to drugs that offer significant improvement compared with products already on the market.

December 18, 2012

The Food and Drug Administration has approved two generic versions of a drug to treat HIV, according to agency records.

SILVER SPRING, Md. — The Food and Drug Administration has approved two generic versions of a drug to treat HIV, according to agency records.

The FDA approved abacavir sulfate tablets in the 300-mg strength made by Apotex and Aurobindo.

The drug is a generic version of Viiv Healthcare's Ziagen.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.